Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

R Burmester, Gerd; B Cohen, Stanley; L Winthrop, Kevin; Nash, Peter; D Irvine, Alan; Deodhar, Atul; Mysler, Eduardo; Tanaka, Yoshiya; Liu, John; P Lacerda, Ana; Palac, Hannah; Shaw, Tim; J Mease, Philip; Guttman‑Yassky, Emma

doi:10.1136/rmdopen-2022-002735

Public

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Shared by NobleBlocks on Feb 1, 2023 • 12:00 AM UTC

Authors:

Gerd R Burmester

Stanley B Cohen

Kevin L Winthrop

Abstract

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD). Methods Safety data from clinical trials of upadacitinib 15 mg and upadacitinib 30 mg (AD only) for treating RA, Ps...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!